Robert W. Ross
Independent DirectorDr. Robert W. Ross, also known as Rob, M.D., is an Independent Director of Obsidian Therapeutics, Inc. He joined Clasp Therapeutics in November 2023. He was President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021 until September 08, 2023. He serves as Independent Director at Xilio Therapeutics, Inc. since June 2022. He serves as Director at Obsidian Therapeutic. He served as Chief Medical Officer of Surface Oncology, Inc. since October 2016 until April 01, 2021 and was responsible for advancing Surface Oncology?s development programs, including SRF231, a fully human CD47 antibody, into and through the clinic. Dr. Ross joins Surface from bluebird bio, where he was head of the Oncology franchise and Senior Vice President of Clinical Development and pharmacovigilance. Prior to Surface, Dr. Ross served as Head of Oncology at bluebird bio, Inc. from October 2015 to October 2016, Senior Vice President of Clinical Development and Pharmacovigilance, from January 2015 to October 2016 and Vice President of Clinical Development, from October 2012 to January 2015. Before bluebird bio, he worked at Genentech and Infinity Pharmaceuticals on both small molecule and antibody programs from Phase 1 through pivotal trials. Prior to that, he worked at Infinity Pharmaceuticals, Inc. from October 2007 to October 2012. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Center from July 2003 to August 2007 and then maintained a clinical practice at Dana Farber Cancer from August 2007 to October 2015. Dr. Ross serves as Director of Obsidian Therapeutics, Inc. Dr. Ross received a B.S. in Biological Sciences and a B.A. in Philosophy from Stanford University, an M.S. in Medical Science as part of the Clinical Investigator Training Program from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco and an oncology fellow in the Dana Farber/Massachusetts General Brigham program.
Positions
- Company NameObsidian Therapeutics, Inc.Stock CodeOBXPositionIndependent DirectorColleagues
